ItalyItaly

New R&D centre

13.07.2009

Parma – Chiesi Farmaceutici S.p.A. has begun building a new EUR70m R&D centre in Parma to study innovative therapies for the treatment of respiratory and special care diseases. The centre, which will be co-financed with funds from the European Investment Bank, is due to start operations in 2011. The new facility is to be staffed by more than 300 scientists, and will focus on relevant chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease, cystic fibrosis and respiratory distress syndrome in premature infants.

ItalyItaly

07.03.2012

Toscana Biomarkers S.r.l has entered the market for biomarkers with its first diagnostic kit. In late January, the company from Siena signed a licence agreement with DIESSE Ricerche S.r.l, based in Genoa. DIESSE will produce and...

ItalyItaly

07.03.2012

Italian researchers have reprogrammed neonatal cardiomyocytes into iPSCs that can re-differentiate toward CMs more efficiently than either cardiac fibroblast-derived iPS cells or even ES cells. (Cell Death Differ.,...

ItalyItaly

09.01.2012

Rome – A cold virus isolated from chimpanzees might work as an vector for human vaccines. Adenoviruses are principally suitable as vectors for vaccines for their ability to induce strong immune responses. But as most humans have...

ItalyItaly

16.12.2011

Milan/Turku – Italian drug developer Newron SpA has had a roller-coaster ride in the last few months. First Merck Serono decided to drop its stake in the company’s Parkinson’s Disease candidate salfinamide, and returned the...

ItalyItaly

15.12.2011

Genoa/Irvine – Researchers from the universities at Genoa and Irvine (US) have patented a new compound that blocks removal of the endo­cannabinoid painkiller anandamide from the synaptic space by a selective transport system....

ItalyItaly

01.10.2011

Parma/Baranzate – Chiesi Farmaceutici Spa has said it will lengthen its long-term collaboration with NiKem Research, which is focused on developing treatments within the respiratory therapeutic area. The two drug developers have...

ItalyItaly

01.10.2011

Milan/Turku – Biotie Therapies ASA’s announcement that it had signed an agreement to acquire Newron Pharma­ceuticals S.p.A. for €45m is both good and bad news for the Italian biotechnology sector. While Italy is losing one of its...

ItalyItaly

19.08.2011

Como – Shares in Gentium SpA lost about a third of their value on Thursday after The Italian biopharmaceutical company withdrew a marketing application for its drug Defibrotide being used against complications related to stem...

ItalyItaly

01.08.2011

Milan/London – Italy’s MolMed SpA has signed a deal with UK-based pharmaceutical giant GlaxoSmithKline to develop a production process for a gene therapy against the rare ‘bubble boy disease’. Over the next two years, GSK will...

Displaying results 1 to 10 out of 181

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-italy/article/new-rd-centre.html

Events

All Events

Stock list

All quotes

TOP

  • NOVACYT (F)4.98 EUR5.96%
  • STALLERGENES (F)53.50 EUR4.37%
  • MORPHOSYS (D)72.25 EUR3.96%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • OREXO (S)137.00 SEK-5.35%

TOP

  • WILEX (D)3.10 EUR307.9%
  • SANTHERA (CH)67.95 CHF88.7%
  • ADDEX (CH)4.03 CHF79.9%

FLOP

  • MERCK KGAA (D)64.38 EUR-49.4%
  • HYBRIGENICS (F)1.77 EUR-27.5%
  • CHRONTECH PHARMA (S)0.07 SEK-22.2%

TOP

  • SANTHERA (CH)67.95 CHF3457.6%
  • GW PHARMACEUTICALS (UK)419.75 GBP715.0%
  • PAION (D)2.77 EUR313.4%

FLOP

  • CYTOS (CH)0.26 CHF-92.4%
  • EVOCUTIS (UK)0.21 GBP-91.8%
  • THROMBOGENICS (B)9.54 EUR-69.5%

No liability assumed, Date: 27.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...


Current issue

All issues

Product of the week

Products